Your Search Results

Inflammation and cardiovascular risk

21 May 2026 – From EuroPCR 2026

Exploring the interplay between inflammation and cardiovascular risk, this session reviews contemporary research on residual risk post-PCI, inflammatory markers in coronary artery disease especially in type 2 diabetes and ACS, and prognostic tools including lipoprotein(a) and systemic inflammation indices.

Modern risk prediction in TAVI

21 May 2026 – From EuroPCR 2026

This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.

The pearl of unloading with mechanical circulatory support

21 May 2026 – From EuroPCR 2026

Delve into the critical aspects of mechanical circulatory support in cardiogenic shock, focusing on device selection, assessment of persistent congestion, and the application of unloading tools to improve patient management and outcomes.

The pearl of unloading with mechanical circulatory support

Haemodynamic support: from shock to complex high-risk interventional problems

21 May 2026 – From EuroPCR 2026

This session examines haemodynamic support from cardiogenic shock through to complex high-risk interventional cardiology procedures. It features registry data, clinical outcomes, and procedural techniques including mechanical circulatory support and arterial access strategies.

Apply now for a chance of granting towards participation at EuroPCR 2024

A limited number of Indirect Industry Supported Grants are available for healthcare practitioners who meet our Industry Partners’ selection criteria

Indirect Industry Supported Grants for EuroPCR 2023

PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction

03 Apr 2022

Nicola Ryan provides a PICOT analysis of PACMAN AMI: a double-blind, placebo-controlled, randomized trial presented at ACC 2022 and simultaneously published in JAMA.